About CHD Risk Assessment

A roundtable meeting with
Dr. Peter McCullough, MD, MPH,
Dr. Jeffrey L. Boone, MD, MS,
Dr. Kenneth E. Blick, PhD, and
Dr. Kenneth Fang, MD, regarding:

  • CHD pathophysiology and disease progression
  • Current gaps in lipid testing
  • Enhancing the lipid profile with additional biomarkers

Dr. Peter McCullough, MD, MPH provides insights about:

  • Understanding lipids and the risk of CHD events
  • Defining the Residual Risk of CHD Events
  • Advances in Laboratory Medicine to Assess CHD

Dr. Jeffrey L. Boone, MD, MS provides insights about:

  • Improving patient risk assessment using advanced diagnostic tools

Importance of Lp-PLA2 as an Objective CHD Risk Assessment Biomarker

In this document, Dr. Jeffery Boone addresses the importance of Lp-PLA2 as an objective CHD risk assessment biomarker. Dr. Boone explains how the PLAC® Activity Test is a critical tool for CHD prevention. The Points from the Literature highlight the REGARDS multicenter sub study and the Lp-PLA2 Activity test cut-point.